#United States #Princeton #Kenox Pharmaceuticals #R&D Leadership #Dr. Julianne Berry

Kenox Pharmaceuticals' New Leadership Announcement

Kenox Pharmaceuticals Inc., a leader in drug-device combination therapies, is excited to announce the appointment of Dr. Julianne Berry as the new Vice President of Research and Development (R&D) and Manufacturing. Dr. Berry's impressive 30-year career in the field of respiratory and specialty products positions her perfectly to drive innovation within the company.

In her new role, Dr. Berry will supervise Kenox's extensive development, manufacturing, and testing operations. Her focus will be on enhancing efficiency and fostering innovation across the company's growing range of inhaled, nasal, and ophthalmic drug-device combination products. This strategic move comes as Kenox continues its commitment to delivering cutting-edge therapies effectively and promptly.

Dr. Berry is renowned in the pharmaceutical industry for her significant contributions to the launch of various successful therapies. She has played a pivotal role in developing and commercializing metered dose inhalers, nasal sprays, dry powder inhalers, and nebulizers, among other specialized products. Her previous leadership positions at prestigious organizations such as Schering-Plough, Merck, Novel, Lupin, Glenmark, and Odin have further underscored her capability and influence in advancing respiratory drug delivery technologies.

Expressing her enthusiasm about joining the Kenox team, Dr. Berry stated, "I am thrilled to join the highly experienced and creative Kenox team committed to accelerating the development of an innovative pipeline of inhaled, intranasal, and ophthalmic products. I'm excited to help bring these life-changing therapies to the clinic faster and ensure that patients gain access as quickly as possible." Her passion for innovation reflects the core values of Kenox Pharmaceuticals, particularly in addressing unmet patient needs.

Dr. Sitaram Velaga, CEO of Kenox Pharmaceuticals, expressed his excitement over Dr. Berry's appointment, saying, "We're delighted to welcome Dr. Berry to Kenox. Her extensive expertise in respiratory and nasal product development, combined with her proven leadership, perfectly aligns with Kenox's mission to deliver next-generation drug-device combination therapies with scientific rigor and operational excellence." This collaboration solidifies Kenox's ambition to be at the forefront of pharmaceutical innovation.

Dr. Berry's arrival is a significant milestone in Kenox's growth journey, marking an era of expanded resources in integrated R&D, fill-finish, and analytical services. As the company continues to enhance its capabilities to support global pharmaceutical and biotech partners, Dr. Berry's leadership will prove invaluable in navigating this growth trajectory.

Kenox Pharmaceuticals, dedicated exclusively to inhalation, intranasal, and ophthalmic therapies, is a specialized Contract Development and Manufacturing Organization (CDMO). By offering fully integrated R&D, fill-finish, and analytical testing services, Kenox empowers pharmaceutical and biotech clients from concept to clinic. As the industry evolves, Kenox remains steadfast in accelerating the development and delivery of innovative drug-device combination products, ensuring improved health outcomes for patients worldwide.

For more information about Kenox Pharmaceuticals and its capabilities, visit www.kenoxpharma.us.